Results 1 to 10 of about 91,870 (284)

Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study

BMC Gastroenterology, 2022
Background Recent studies have confirmed that combined surgery and anti-TNF therapy could improve outcomes in patients with perianal fistulising Crohn’s disease (PFCD).
Ping Zhu, Jin-fang Sun, Yun-fei Gu, Hong-jin Chen, Min-min Xu, You-ran Li, Bo-lin Yang   +6 more
doaj   +1 more source

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

Gut and Liver, 2023
Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861).
Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber   +9 more
doaj   +1 more source

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. [PDF]

PLoS ONE, 2018
Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis.In a ...
Jessica R de Bruyn, Marte A Becker, Jessica Steenkamer, Manon E Wildenberg, Sybren L Meijer, Christianne J Buskens, Willem A Bemelman, Mark Löwenberg, Cyriel Y Ponsioen, Gijs R van den Brink, Geert R D'Haens   +10 more
doaj   +1 more source

In vivo evaluation of TNF-alpha in the lungs of patients affected by sarcoidosis [PDF]

, 2015
Introduction. Sarcoidosis is a multisystemic granulomatous disorder characterized by multiple noncaseating granulomas involving intrathoracic lymph nodes and lung parenchyma.
BRUNO, PIERDONATO, GALLI, FILIPPO, LANZOLLA, TIZIANA, Malviya, Gaurav, MARIOTTA, Salvatore, PIETRANGELI, VITTORIO, Ragni, Paola, RICCI, Alberto, SCOPINARO, Francesco, SIGNORE, Alberto   +9 more
core   +10 more sources

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events

Current Oncology, 2021
Background and aims: Current guidelines state that infliximab is contraindicated for the treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing further liver damage.
Daniel V. Araujo, Thiago Pimentel Muniz, Anjie Yang, Sareh Keshavarzi, Hadas Sorotsky, Marcus O. Butler, Samuel Saibil, Anna Spreafico, David Hogg   +8 more
doaj   +1 more source

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]

, 2020
ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick, Curtis, Jeffrey R, Evans, Michael, He, Zeling, Huang, Jie, Johansson, Tracy, Liao, Katherine P, Michaud, Kaleb, Schmajuk, Gabriela   +8 more
core   +1 more source

Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels

Heliyon, 2023
Infliximab and its anti-drug antibody (ADA) serum concentrations exhibit a strong correlation with clinical response and loss of response. The use of therapeutic drug monitoring to measure the concentration of infliximab and ADA can facilitate clinical ...
Dong Xiang, Ninghong Li, Lu Liu, Hengyi Yu, Xiping Li, Tinghui Zhao, Dong Liu, Xuepeng Gong   +7 more
doaj   +1 more source

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

Frontiers in Pharmacology, 2020
ObjectiveTo compare the market dynamics of biosimilar infliximab among four Organization for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and Korea) where supply-side and demand-side policies varied greatly, given high and ...
Yujeong Kim, Hye-Young Kwon, Hye-Young Kwon, Brian Godman, Brian Godman, Brian Godman, Evelien Moorkens, Steven Simoens, SeungJin Bae   +8 more
doaj   +1 more source

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report

BMC Gastroenterology, 2021
Background Infliximab-induced seizures in patients with Crohn’s disease are extremely rare and the mechanism of infliximab-induced seizures is unclear.
Zhijie Lv, Xiaoqi Zhang, Li Wu
doaj   +1 more source

Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis [PDF]

, 2013
Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumatoid arthritis (RA). It is unknown why some RA patients fail to respond adequately to anti-TNF therapy, which limits the development of clinical biomarkers ...
A Parker, AI Catrina, AL Price, Alison Motsinger-Reif, AM van Gestel, Ann W. Morgan, Anne Barton, Anthony G. Wilson, Atsuo Taniguchi, B Devlin, Barbara E. Stranger, BE Stranger, BJ Scallon, C Liu, C Miceli-Richard, Chikashi Terao, Corinne Miceli, Cornelia F. Allaart, D Aeberli, D Plant, D Plant, DL Scott, Dorothee Diogo, EA Stahl, EA Stahl, EJ Toonen, Eli A. Stahl, Elizabeth W. Karlson, FM Batliwalla, Fumihiko Matsuda, Gert Jan Wolbink, GM Cooper, Gosia Trynka, H Canhao, Helena Canhao, Henk-Jan Guchelaar, Hisashi Yamanaka, IB McInnes, Irene E. van der Horst-Bruinsma, J Agnholt, J Cui, J Ernst, J Marchini, J. Bart A. Crusius, Jing Cui, Johan Askling, John D. Isaacs, João Eurico Fonseca, Katsunori Ikari, Kimme L. Hyrich, Koichiro Ohmura, L Klareskog, L Padyukov, Larry W. Moreland, LD Ward, Leonid Padyukov, Lindsey A. Criswell, M Martin, Manik Kuchroo, Marieke E. Doorenspleet, Marieke Herenius, Marieke J. H. Coenen, Mart van de Laar, Maša Umiċeviċ Mirkov, Michael E. Weinblatt, MJ Coenen, ML Prevoo, MM Soliman, Namrata Gupta, Nancy A. Shadick, Niek de Vries, O Stegle, Paul-Peter Tak, Peter K. Gregersen, Philip L. De Jager, PI de Bakker, Piet L. C. M. van Riel, PL De Jager, R Prajapati, Rene E. M. Toes, RM Plenge, Robert M. Plenge, Robert P. Kimberly, S Gudbrandsdottir, S Purcell, S. Louis Bridges, SA Gauthier, Saedis Saevarsdottir, Sara Wedrén, SG Tangye, Shigeki Momohara, Soumya Raychaudhuri, Tom W. J. Huizinga, Towfique Raj, Tsuneyo Mimori, Xavier Mariette, Y Okada, Yukinori Okada   +97 more
core   +17 more sources